A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer
Clinical trial NCT05380024 · UNKNOWN
Trial details
- NCT number
- NCT05380024
- Sponsor
- Peking University Cancer Hospital & Institute
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-17
- Primary completion
- 2023-12-30
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.